Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt

Kidney Disease: early-phase trial registry

11 of 24 indexed Kidney Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #686 of 28,707 conditions by registered trial count.

24 US clinical trials · 11 currently recruiting · #686 of 28,707 conditions by registered trial count

Kidney Disease: 24 US clinical trials tracked, 11 recruiting.

Kidney Disease is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 2 of these trials.

Enrollment posture brief

Registry condition kidney-disease

OPEN 11 | RECR 46% | LATE 3 | EARLY 6 | RANK #686 | SPON 2

Nearest open-share peer: Glaucoma Open-Angle (46% recruiting · 24 trials)

Kidney Disease (this)46%Aplastic Anemia37.5%Behavior37.5%Allergic Rhinitis8.3%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Kidney Disease

Kidney Disease lists 11 open slots (46% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Kidney Disease is recruiting above its size-band peers.

    11 of 24 indexed trials (45.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Kidney Disease trials is spread across many organizations.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 2 of 24 trials (8.3%). 22 distinct sponsors appear on at least one study for this condition label.

  3. Typical Kidney Disease enrolment sits around 120 participants.

    Median target enrolment is 120 among the 24 trials that report a genuine target (sentinel values excluded). 11 of those (45.8%) plan for fewer than 100 participants.

  4. Kidney Disease splits between interventional and observational designs.

    15 interventional and 9 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 31Phase 42

Open and recent trials

24 total, page 1 of 1

RECRUITING 50,000 participants

Rutgers University Study of the Genetics of Kidney Disease

Rutgers, The State University of New Jersey

NCT07217535

RECRUITING 2,000 participants

Immune System Related Kidney Disease

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00001979

RECRUITING 400 participants

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

Devyser

NCT07006831

RECRUITING Phase 3 347 participants

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Takeda

NCT06963827

RECRUITING NA 300 participants

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Aventyn

NCT07403669

RECRUITING Phase 4 200 participants

Randomized Trial of SGLT2i in Heart Transplant Recipients

VA Office of Research and Development

NCT06625073

RECRUITING 125 participants

Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)

Bodyport

NCT07059962

RECRUITING NA 120 participants

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Well Cell Global

NCT07187479

RECRUITING Phase 2 118 participants

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

University of Colorado, Denver

NCT04040959

RECRUITING NA 90 participants

Inspire HER: Inspiring the Heart and Emotions for Radical Health

University of Alabama at Birmingham

NCT06966258

RECRUITING Phase 1 28 participants

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Eli Lilly and Company

NCT07426380

COMPLETED NA 12,108 participants

Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research

Vanderbilt University Medical Center

NCT02660931

COMPLETED Phase 4 777 participants

ISCHEMIA-Chronic Kidney Disease Trial

NYU Langone Health

NCT01985360

COMPLETED 634 participants

The Drug Induced Renal Injury Consortium

Ravindra Mehta

NCT02159209

COMPLETED 150 participants

Evaluation of New Test Method to Measure Kidney Function

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00026715

COMPLETED NA 48 participants

Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease

Atlanta VA Medical Center

NCT00781417

COMPLETED 44 participants

A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome

University of Minnesota

NCT00622544

COMPLETED NA 43 participants

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Myles Wolf

NCT00843349

COMPLETED 30 participants

DBS for Home Monitoring in Children With Kidney Transplantation

Oregon Health and Science University

NCT01931397

COMPLETED Phase 1 17 participants

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

Trevena

NCT01444872

COMPLETED Phase 2 11 participants

Trial of Oral Glutamine on Mitochondrial Function in CKD

University of Washington

NCT02838979

COMPLETED Phase 2 10 participants

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Akebia Therapeutics

NCT01235936

COMPLETED Phase 1 10 participants

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

University of Wisconsin, Madison

NCT00078559

COMPLETED 8 participants

Role of Nox2 in CNI-induced Renal Fibrosis

University of Wisconsin, Madison

NCT01674465

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 1
Phase 4 2

Named interventions

Most-linked intervention names on Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
AKI Risk Notification Other
1 trials
Percutaneous Coronary Intervention Procedure
1 trials
Coronary Artery Bypass Graft Surgery Procedure
1 trials
Second Intervention (14 days) Dietary supplement
1 trials
Washout (3 weeks) Other
1 trials
First Intervention (14 days) Dietary supplement
1 trials
Methylprednisolone (or equivalent) Drug
1 trials

US sites by state

Facility locations filed on Kidney Disease trials. A trial with sites in several states counts in each.

Georgia 5 trials
California 5 trials
Florida 4 trials
Wisconsin 3 trials
Texas 3 trials
Tennessee 3 trials
Minnesota 3 trials
Maryland 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Kidney Disease page

24 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Disease condition card totals 24 registered trials; most-linked intervention Placebo; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.